Six structural pressures shape every health plan’s cardiac surgical line. Each one has the same upstream solution: specialist-led decision support before authorization.
37–66% of cardiac second opinions result in a changed or refined treatment plan. Every avoidable cardiac procedure carries $40K–$90K+ in direct surgical cost plus weeks of post-acute claims.
Only 16% of physicians believe the reviewer in current prior authorization is qualified for the case under review (AMA 2024). Cardiac surgical decisions are reviewed by cardiologists and general UM physicians who do not perform the procedures.
Approximately 80% of cardiac PA denials are overturned on appeal. Under CMS-0057-F (effective January 2026), overturn rates become public. Plans whose decisions cannot survive scrutiny will be visible to members, employers, and regulators.
A single redirected cardiac case can swing $36K–$150K in plan spend. A prevented complication saves $300K–$600K+. Without specialist-level review at the front of the funnel, the variance is uncontrolled.
Cardiac is consistently the highest-cost surgical category in any commercial or Medicare Advantage book. Marginal MLR improvement requires intervention upstream of the OR — not retrospective claim adjudication.
H.R. 2433 advances same-specialty reviewer requirements for Medicare and Medicare Advantage. The trajectory is clear: cardiac surgery decisions will require cardiac surgeons. Plans must be ready before the mandate, not after.
Generalist UM vendors review cardiac surgical decisions with cardiologists or general internists. WhiteGloveMD reviews them with the cardiac surgeons who actually perform these procedures — with structured risk quantification on every case.
Every case is reviewed by a world-class cardiac surgeon plus an interventional cardiologist — dual-signed. Not a UM cardiologist who does not perform the procedure. Not an offshore generalist. The same surgeons who would perform the operation are the ones reviewing whether it should be performed.
STS, EuroSCORE II, and AATS risk scoring run on every case. The plan receives an objective surgical risk profile — mortality, complications, length of stay, readmission probability — not a clinical opinion. Every recommendation is source-linked to the medical record.
Independent specialist review redirects 37–66% of cardiac surgical recommendations to medical management, alternative procedures, or higher-volume centers with better outcomes. The plan funds a $495 review and avoids a $40K–$90K procedure that should not have happened.
Beyond avoided procedures: prevented complications ($300K–$600K each), reduced 30-day readmissions, optimized surgeon-case matching, and shorter post-acute trajectories. Every component compounds into MLR improvement.
Every figure on this page comes from published clinical literature, federal benchmarks, or platform data. Nothing is modeled, projected, or extrapolated.
A $495 specialist review prevents a $40K–$90K procedure roughly one in three times. The math does not require a complicated model.
Two regulatory developments are reshaping cardiac prior authorization. Both push toward the architecture WhiteGloveMD already operates.
Advances same-specialty reviewer requirements for Medicare Advantage prior authorization. Cardiac surgical decisions reviewed by a cardiologist or generalist would not satisfy the standard. The same surgeon-led review WhiteGloveMD performs today is the default that the legislation pushes toward.
Mandates faster prior-authorization decisions, electronic PA APIs, and public reporting of approval rates, denial rates, and overturn-on-appeal rates. Plans whose cardiac denials are overturned at high rates will have that data exposed. The pressure to get the initial decision right — with a qualified reviewer — is intensifying.
Plans that build same-specialty review architecture before the mandate land in compliance ahead of competitors. Plans that wait absorb the operational disruption later.
Same Heart Team, same risk scoring, same 24-hour turnaround. Different commercial structures depending on whether the plan deploys WhiteGloveMD as a member benefit or as a case-by-case decision-support layer.
Plans frequently begin with a PA decision-support pilot on cardiac surgical PAs, then expand to a member-benefit structure once outcomes data validates the case. We support both motions and the transition.
Schedule a confidential pilot call. We’ll structure a 30–60 day program around your cardiac PA volume.